Ergomed Strengthens Executive Management Team
17/11/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221117:nRSQ6936Ga&default-theme=true
RNS Number : 6936G Ergomed plc 17 November 2022
PRESS RELEASE
Ergomed Strengthens Executive Management Team
Michael Spiteri moves from Board to take up Executive Role as Chief
Transformation and Technology Officer
Jonathan Curtain joins as Deputy CFO from ICON plc
Guildford, UK - 17 November 2022: Ergomed plc (LSE: ERGO) ("Ergomed" or the
"Company"), a company focused on providing specialised services to the
pharmaceutical industry, today announces it has further strengthened its
Executive Management Team with two significant senior appointments.
In line with the continued strengthening of our management team and our
commitment to maximising the potential of technology across the business,
Michael Spiteri has been appointed as Chief Transformation and Technology
Officer ("CTTO"). As a result of the appointment, Michael has stepped down as
a Non-Executive Director with immediate effect.
Michael has over 30 years' experience working in information technology and
digital transformation with companies including Santander, Elixirr Partners,
PwC, Accenture and IBM. He was previously Global Head of Insurance
Transformation and Innovation, HSBC Life and Partnerships at HSBC. Michael
specialises in helping organisations implement technology that transforms
their business and operating models and, since joining Ergomed's Board of
Directors in 2018, has helped Ergomed develop its capabilities across digital,
automation and machine learning.
In addition, Jonathan Curtain has been appointed as Deputy Chief Financial
Officer. Jonathan has extensive life sciences industry experience, having
spent 13 years with ICON plc, a leading global CRO business listed on the
NASDAQ with a market capitalization of $16 billion. Most recently, he was the
Senior Vice President of Corporate and Commercial Finance, where he had a
broad range of responsibilities including financial reporting, acquisitions
and post-acquisition integration, debt and equity fundraising, treasury and
overall financial management. During his time with ICON, he has also led the
Investor Relations function and played a key role in transactions worth over
$13.5 billion including most recently the $12 billion acquisition by ICON of
PRA Health Sciences Inc. Jonathan has over 20 years' experience as a Chartered
Account after receiving his ACA qualification at KPMG.
Dr. Miroslav Reljanović, Executive Chairman of Ergomed, commented: "I am
excited to be announcing these two appointments to further strengthen our
Executive Management Team.
Since joining our Board in 2018, Michael Spiteri's strategic insight has been
extremely valuable to us as we have developed our strategy of digital
transformation across the business. I am excited by Michael joining the
Executive Management Team as CTTO to utilise his years of technology and
transformation experience, which over time will become central to Ergomed's
continued transformation and growth. His appointment demonstrates Ergomed's
continued focus on becoming a leader in the application of digital technology
in the pharmaceutical services industry, and I look forward to working more
closely with him moving forward.
"I also welcome Jonathan Curtain to Ergomed. He has deep CRO industry
experience from his 13 years with ICON and I believe his close involvement in
ICON's significant growth, strategic M&A and post-acquisition integration
will allow him to strengthen Ergomed's ability to deliver further success and
strategic development internationally."
Michael Spiteri, CTTO, commented: "Technology has the potential to
revolutionise clinical trials and the pharmacovigilance market and has become
particularly relevant in the wake of the COVID-19 pandemic. Having worked
closely with the Board as a Non-Executive Director for four years, I have seen
first-hand the Company's success in developing and investing in technology to
further enhance its service offerings. With this focus, I firmly believe that
Ergomed is well placed to continue to develop a leading digital technology
offering to drive efficiency and accuracy across the business for the benefit
of our customers and, ultimately, patients."
Jonathan Curtain, Deputy CFO, said: "I am delighted to be joining Ergomed at
this exciting time in the Company's development. I believe Ergomed is
exceptionally strongly positioned to continue its growth and expansion and I
look forward to working with the Executive Management Team and Board to
continue on that trajectory through strong organic growth augmented by highly
strategic acquisitions."
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402 975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital Markets & Strategy)
Numis (Nominated Adviser and Joint Broker) Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP (Joint Broker) Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher
Golden
Consilium Strategic Communications - for UK enquiries Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal / Angela Gray ergomed@consilium-comms.com (mailto:ergomed@consilium-comms.com)
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing services business includes an
industry-leading suite of specialist pharmacovigilance (PV) solutions,
integrated under the PrimeVigilance brand, a full range of high-quality
clinical research and trial management services under the Ergomed brand (CRO)
and mission-critical regulatory compliance and consulting services under the
ADAMAS brand. For further information, visit: http://ergomedplc.com
(http://ergomedplc.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCDBBDBDUBDGDL